About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Alzheimer's and Amyloid, Again | Main | How Sleazy It Can Get »

July 27, 2010

Genzyme Telling Sanofi-Aventis to Buzz Off?

Email This Entry

Posted by Derek

That's what Bloomberg is reporting. Meanwhile, the Wall Street Journal reported that GlaxoSmithKline has expressed interest in the recent past, and that J&J might get involved as well. If a deal goes through, no matter who ends up making it, it'll be a lot more expensive than it looked like being. But isn't that ever the way in M&A? The problem is, everyone except the buyer has a great interest in seeing things go off at the highest possible price.

Comments (4) + TrackBacks (0) | Category: Business and Markets


1. Old Timer on July 27, 2010 9:44 AM writes...

Great for Genzyme shareholders if they can get GSK to grab the dangling bait. Witty is willing to overpay for any biotech that grabs his fancy, as he IS AN EXPERT. Also good for Genzyme management and employees, as the biotech's people will be integrated into the more traditional R&D business since they know better the workings of the new world order (despite having had to sell themselves), the Cambridge site would be left intact as an independent DPU, with cost savings being absorbed from GSK's traditional small molecule areas and core R&D sites. What you say? Who needs chemists?

Sorry GSKers, but this would only trigger another yearly "adjustment" coming from the stability promised from your 3-year funding cycle.

Permalink to Comment

2. Hap on July 27, 2010 10:15 AM writes...

This seems way too much like a page out of Atlas Shrugged to be of any particular comfort.

Permalink to Comment

3. DannoH on July 27, 2010 12:13 PM writes...

Its similar to Sanofi-Aventis telling FDA to buzz off. Lets see how well that works out when SA gets their next few general inspections from CBER.

Permalink to Comment

4. Hap on July 28, 2010 8:58 AM writes...

...except Genzyme doesn't need S-A - they want their money, but GSK's money is just as good (well, if there's enough of it) or J+J's. On the other hand, if you can't sell product in your biggest market, you're SOL.

I think the FDA has a little more leverage over S-A than S-A has over Genzyme at this point.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry